5 results about "Systemic inflammatory response syndrome" patented technology

The present invention relates to the early treatment, including pre-diagnosis treatment, of sepsis and acute inflammatory syndromes such as systemic inflammatory response syndrome (SIRS) by PLA2 and metalloprotease inhibitors to improve the performance of antibiotics and outcomes prior to and after confirmation of the diagnosis of sepsis and / or SIRS in a patient or subject. Additional embodiments include methods of treating sepsis, anthrax and severe acute respiratory syndrome coronavirus (SARS and SARS-CoV2) and related inflammatory syndromes and compositions, including pharmaceutical compositions and blood sample compositions. In further embodiments, the present invention is directed to embodiments which evidence that LY315920, LY333013 and related sPLA2 inhibitors are particularly effective COVID-19 / cytokine release syndrome therapeutics-prophylactics. In embodiments, the PLA2 inhibitor is varespladib (LY315920), methyl varespladib (LY333013), AZD2716-(R)-3-(5′-benzyl-2′-carbamoyl-[1,1′-biphenyl]-3-yl)-2-methylpropanoic acid—as a racemic mixture or separately, as the “R” enantiomer), compound 4 (3-(5′-benzyl-2′-carbamoyl-[1,1′-biphenyl]-3-yl)-propanoic acid) and LY433771 ((9-[(phenyl)methyl]-5-carbamoylcarbazol-4-yl) oxyacetic acid), a pharmaceutically acceptable salt thereof or a mixture thereof. In embodiments, the metalloprotease inhibitor is Prinomastat, Batimastat, marimastat or vorinostat dosed alone or in combination with preferred sPLA2 inhibitors for the treatment of infection, inflammatory and wound conditions arising from various causes. Methods and compositions for achieving accelerated treatment of wounds and burns, anthrax metalloprotease toxin (lethal factor) driven complications, ARDS, neo-natal and pediatric acute respiratory distress syndrome (neo-natal / pediatric ARDS), including meconium aspiration syndrome and other disease states and conditions are also disclosed.

The invention discloses application of 1, 5-anhydro-D-sorbitol (1, 5-anhydroglaucitol, called 1, 5-AG for short) in inhibition of activation of NLRP3 inflammasomes, and particularly discloses application of 1, 5-anhydro-D-sorbitol (1, 5-AG for short) in inhibition of activation of NLRP3 inflammasomes. The invention relates to an application of 1, 5-anhydro-D-sorbitol in preparation of a medicine for inhibiting activation of NLRP3 inflammasomes, in particular to an application of 1, 5-anhydro-D-sorbitol. The NLRP3 inflammasome activation related diseases are selected from septicaemia induced by LPS, gouty arthritis induced by MSU, non-alcoholic fatty liver disease, systemic inflammatory response syndrome or inflammatory bowel disease. The 1, 5-AG is combined with an NATCH structural domain of the NLRP3 protein, so that the interaction between the 1, 5-AG and NEK7 and ASC is inhibited. The invention relates to an application of 1, 5-anhydro-D-sorbitol in preparation of functional food for inhibiting activation of NLRP3 inflammasomes. The 1, 5-AG is natural in source, high in oral bioavailability and high in safety, and has the advantage of being further developed into inflammation regulation drugs or dietary supplements.

The present invention relates to the use of albumin for regulating immune cells in subjects requiring it. In particular, the present invention relates to compositions comprising human albumin for use in regulating immune cells in subjects having systemic inflammatory response syndromes.

The application belongs to the technical field of biological medicine, and particularly relates to application of (E)-BCI hydrochloride in preparation of a medicine for treating sepsis. The application provides application of (E)-BCI hydrochloride in preparation of the medicine for treating sepsis. (E)-BCI hydrochloride regulates a DRD1 gene through targeting, quiets an interferon stimulation storm, reduces abnormal activation of astrocytes, reduces a level of an inflammatory factor, improves expression of a nerve activity gene, and provides a non-antibiotic dependent medicine for sepsis treatment from a new target point of regulating inflammation and immune balance, and is particularly suitable for systemic inflammatory response syndrome caused by various causes such as infection, operation and trauma, and has a wide clinical application prospect.

Provided herein are compositions and methods related to the treatment of acute pancreatitis (AP) in subjects having accompanying Systemic Inflammatory Response Syndrome (SIRS). The present disclosure provides a method for treating AP including administering a therapeutically effective amount of an intracellular calcium signaling inhibitor to a subject, wherein said subject optionally has accompanying systemic inflammatory response syndrome (SIRS).